A clinical research on oxymatrine for the treatment of chronic hepatitis B.
- Author:
Yan Yan YU
1
;
Qin Huan WANG
;
Li Min ZHU
;
Qing Bo ZHANG
;
Dao Zhen XU
;
Yan Bin GUO
;
Chao Quan WANG
;
Shu Hua GUO
;
Xia Qiu ZHOU
;
Ling Xia ZHANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adolescent; Adult; Alkaloids; adverse effects; therapeutic use; Antiviral Agents; therapeutic use; Female; Hepatitis B, Chronic; drug therapy; Humans; Male; Middle Aged; Quinolizines
- From: Chinese Journal of Hepatology 2002;10(4):280-281
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical effect of oxymatrine on chronic viral hepatitis B and to look for new methods for treating hepatitis B.
METHODSMulti-center, controlled study was used. In this study, 196 patients were allocated to oxymatrine, oxymatrine with Ara-AMP, IFN-a1b, and glucose groups to observe ALT, AST and viral marker changes.
RESULTSAt the end of treatment, the rate of normal ALT, the negative rate of HBV DNA and HBeAg, and the positive rate of HBeAb were similar in oxymatrine, oxymatrine with Ara-AMP, and IFN-a1b groups. It was higher than that of glucose group. After 12 months follow up, the total effective rate is 40.8%, 60.8% and 43.1% in oxymatrine, oxymatrine with Ara-AMP, and IFN-a1b groups, respectively.
CONCLUSIONSOxymatrine, oxymatrine with Ara-AMP, and IFN-a1b are effective to treat hepatitis B with a good negative rate of HBV DNA and HBeAg and positive rate of HBeAb.
